@prefix rdfs:    <http://www.w3.org/2000/01/rdf-schema#> .
@prefix foaf:    <http://xmlns.com/foaf/0.1/> .
@prefix owl:     <http://www.w3.org/2002/07/owl#> .
@prefix vocabProperty:  <http://www4.wiwiss.fu-berlin.de/drugbank/vocab/resource/property/> .
@prefix drugbank:  <http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/> .
@prefix dbpedia:  <http://dbpedia.org/ontology/> .
@prefix map:     <file:/C:/apps/drugbank/drugbank.n3#> .
@prefix rdf:     <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix trc:     <http://www.trialresultscenter.org/property/> .
<http://www.trialresultscenter.org/study8813-WAFACS.htm>    <trc:trial_id>8813</trc:trial_id>spc+<trc:name>WAFACS, 2008</trc:name>spc+<trc:registre>NCT00000541</trc:registre>    trc:studiedTreatment "folic acid 2.5mg, vitamin B6 50mg, and vitamin B12 1mg daily";    <trc:studiedTreatmentDetail><![CDATA[]]></trc:studiedTreatmentDetail>    <trc:controlTreatment><![CDATA[placebo]]></trc:controlTreatment>    <trc:controlTreatmentDetail><![CDATA[]]></trc:controlTreatmentDetail>    <trc:concomittantTreatment><![CDATA[]]></trc:concomittantTreatment>    <trc:patients><![CDATA[women aged 42 years or older, with either a history of CVD or 3 or more coronary risk factors]]></trc:patients>    <trc:exclusionCriteria><![CDATA[history of cancer (excluding nonmelanoma skin cancer) within the past 10 years, any serious non-CVD illness, or were currently using warfarin or other anticoagulants]]></trc:exclusionCriteria>    <trc:inclusionCriteria><![CDATA[40 years or older, postmenopausal
or had no intention of becoming
pregnant, and had a reported
history of CVD or had at least 3 cardiac
risk factors;]]></trc:inclusionCriteria>    <trc:exclusionReason><![CDATA[]]></trc:exclusionReason>    <trc:N1>2721</trc:N1>    <trc:N0>2721</trc:N0>    <trc:design>Parallel groups</trc:design>    <trc:inclusionPeriod>jun 1995 - oct 1996</trc:inclusionPeriod>    <trc:blindness>double blind</trc:blindness>    <trc:FUduration>7.3 y</trc:FUduration>    <trc:lostFU></trc:lostFU>    <trc:comment></trc:comment>    <trc:primaryEndpoint>cardiovascular events</trc:primaryEndpoint><trc:demonstratedBenefit>yes</trc:demonstratedBenefit>    <trc:jadad>5</trc:jadad>    <trc:centre></trc:centre>    <trc:area>US</trc:area>    <trc:remarkTreatment><![CDATA[]]></trc:remarkTreatment>    <trc:remarkPatient><![CDATA[]]></trc:remarkPatient>    <trc:remarkMethod><![CDATA[]]></trc:remarkMethod>    <trc:hypothesis>Superiority</trc:hypothesis>    <trc:register>NCT00000541</trc:register>    <trc:studyType>1</trc:studyType>    <trc:question>cardiovascular prevention plasma homocysteine lowering intervention all type of patients</trc:question>    <trc:pathology>cardiovascular prevention</trc:pathology>    <trc:mecanism>plasma homocysteine lowering intervention</trc:mecanism>    <trc:patient>All type of patient</trc:patient>